Experience

We advised the initial purchasers on the high-yield notes offering

We advised the underwriters in connection with the SEC-registered offering

Davis Polk advised the sales agents on the SEC-registered at-the-market offering by RAPT Therapeutics, Inc. of its common stock for up to an aggregate amount of $100 million. RAPT…

Davis Polk advised Signify Health on its acquisition of PatientBlox. The acquisition accelerates Signify’s prospective provider payment capabilities for episodes of care, supporting the…

Davis Polk advised the representative of the several underwriters in connection with the SEC-registered offering of 38,000,000 shares of common stock of Plug Power Inc. for $845.5…

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 5,980,000 shares of common stock of ChemoCentryx, Inc. (which…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Datadog, Inc. of $747.5 million aggregate principal amount of its 0.125%…

Davis Polk advised the underwriters in connection with a $75 million public offering of common stock by RAPT Therapeutics, Inc. RAPT Therapeutics’ common stock is listed on the …

Davis Polk advised the joint book-running managers in connection with an initial public offering of 10,586,316 shares of common stock of Black Diamond Therapeutics, Inc. In addition,…

Davis Polk advised the underwriters in connection with a $38.4 million initial public offering of common stock of RAPT Therapeutics, Inc. RAPT Therapeutics’ common stock is listed on…